4D Molecular Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held virtually on June 17, 2025. As of the record date (April 21, 2025), there were 46,324,642 shares of common stock outstanding. A total of 38,470,536 shares were voted on four proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
- Proposal 1 (Election of Directors): Stockholders elected three Class II director nominees to serve until the 2028 Annual Meeting:
- Jacob Chacko, M.D., MBA: 28,579,453 votes for.
- Susannah Gray, MBA: 31,923,027 votes for.
- Charles P. Theuer, M.D., Ph.D.: 27,285,806 votes for.
- Proposal 2 (Auditor Ratification): Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (38,380,552 votes for).
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the named executive officers' compensation (31,841,967 votes for).
- Proposal 4 (Say-on-Pay Frequency): Stockholders approved holding future advisory votes on executive compensation on an annual basis (32,152,558 votes for).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the full text of the Definitive Proxy Statement (Schedule 14A) filed on April 29, 2025, for details on director biographies and executive compensation specifics.
- Confirm the company's financial status and cash runway through the most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Note that the Board has determined future say-on-pay votes will occur annually based on the stockholder vote.